亚洲AV无码精品一区二区在线|国产免费播放一区二区三区|最新人妻无码不卡在线|亚洲成人在线电影

您的位置:中國博士人才網(wǎng) > 博士后招收 > 研究院所博士后招收 > 首都醫(yī)學(xué)科學(xué)創(chuàng)新中心周欣實(shí)驗(yàn)室2025年招聘助理研究員、博士后

關(guān)注微信

首都醫(yī)學(xué)科學(xué)創(chuàng)新中心周欣實(shí)驗(yàn)室2025年招聘助理研究員、博士后

時間:2025-04-23來源:中國博士人才網(wǎng) 作者:佚名

一、中心簡介

首都醫(yī)學(xué)科學(xué)創(chuàng)新中心(簡稱創(chuàng)新中心)是北京市新成立的具有獨(dú)立法人資格的新型研發(fā)機(jī)構(gòu)。創(chuàng)新中心以推動醫(yī)學(xué)科學(xué)發(fā)展、改善人類健康為目標(biāo),開展生物醫(yī)學(xué)研究,致力于提升醫(yī)學(xué)科學(xué)創(chuàng)新與成果轉(zhuǎn)化能力,提高疾病診斷和治療水平。我們將匯聚世界高水平科學(xué)家,與首都醫(yī)學(xué)教育和科學(xué)研究優(yōu)質(zhì)資源緊密合作,打造多學(xué)科交叉融合的科研平臺,綜合自由探索、醫(yī)學(xué)目標(biāo)導(dǎo)向、有組織科研等途徑,實(shí)踐新型科研模式和體制機(jī)制,逐步推進(jìn)醫(yī)教研產(chǎn)的深度融合,培養(yǎng)適應(yīng)醫(yī)學(xué)科學(xué)創(chuàng)新發(fā)展的優(yōu)秀人才。

二、實(shí)驗(yàn)室介紹

周欣研究員先后在吉林大學(xué)、中國科學(xué)院分子細(xì)胞科學(xué)卓越創(chuàng)新中心(生物化學(xué)與細(xì)胞生物學(xué)研究所)獲得學(xué)士博士學(xué)位,北卡羅來納大學(xué)教堂山分校從事博士后研究,即將加入首都醫(yī)學(xué)科學(xué)創(chuàng)新中心(CIMR)創(chuàng)建獨(dú)立實(shí)驗(yàn)室。

嵌合抗原受體細(xì)胞免疫療法(CAR-T)是一種工程化人體免疫細(xì)胞來殺傷腫瘤的新型免疫治療療法,在白血病、淋巴瘤、多發(fā)性骨髓瘤中取得了備受矚目的療效,目前全球已有多款商業(yè)化產(chǎn)品,但在實(shí)體腫瘤中療效還有諸多挑戰(zhàn)。周欣研究員長期專注于開發(fā)和優(yōu)化新型CAR-T細(xì)胞免疫療法,探索提高CAR-T免疫療法在實(shí)體瘤中療效的細(xì)胞工程策略。實(shí)驗(yàn)室的研究以滿足CAR-T在實(shí)體瘤中轉(zhuǎn)化應(yīng)用的迫切臨床需求為導(dǎo)向,圍繞CAR免疫療法在實(shí)體瘤治療中的挑戰(zhàn),將開展基礎(chǔ)和轉(zhuǎn)化研究。

掃碼查看詳情_二維碼(請點(diǎn)擊鏈接查看詳情)

三、實(shí)驗(yàn)室研究方向

實(shí)驗(yàn)室將綜合利用分子生物學(xué)、細(xì)胞生物學(xué)、流式細(xì)胞術(shù)、小鼠腫瘤模型、高通量測序等技術(shù)和手段,開展(不限)以下課題研究:

l        開發(fā)新型靶向?qū)嶓w腫瘤(如胰腺癌)的CAR-NKT細(xì)胞療法;

l        探索現(xiàn)有兩種不同CAR-T產(chǎn)品(以CD28和以41BB為共刺激分子)細(xì)胞通路機(jī)制,以期開發(fā)下一代CAR-T產(chǎn)品;

l        高通量測序篩選理解腫瘤細(xì)胞耐受CAR-T療法的機(jī)制,以期指導(dǎo)靶向聯(lián)合治療手段。

四、主要成果與貢獻(xiàn)

1.成功構(gòu)建小鼠CAR-NKT細(xì)胞平臺,并證明其可以通過調(diào)控腫瘤微環(huán)境,在多種實(shí)體腫瘤中展現(xiàn)出更強(qiáng)的抗腫瘤效果(Nature Cancer, 2024)。

2.通過修改優(yōu)化CAR分子結(jié)構(gòu)來增強(qiáng)CAR-T治療的療效(Journal for Immunotherapy of Cancer, 2021; Nature Cancer, 2021; Cellular & Molecular Immunology, 2024)(專利,2021, WO2023199069A1)。

3.探索調(diào)控巨噬細(xì)胞中炎癥產(chǎn)生的新的分子機(jī)制以及在炎癥相關(guān)疾病中的作用的功能(Cell Reports, 2019, 2020; The Journal of Clinical Investigation, 2015)。

五、代表性文章

Nature Cancer, 2024 Nov; 5(11): 1607-1621.PMID: 39354225.

Cellular & Molecular Immunology, 2024 Aug; 21(8): 905-917.PMID: 38937625.

Journal for Immunotherapy of Cancer, 2021 Apr; 9(4): e002173.PMID: 33795386.

Cell Reports.2019 Apr 23; 27(4): 1176-1189.e5.PMID: 31018132.

六、崗位信息

01助理研究員

1)主要職責(zé)

1.在PI指導(dǎo)下獨(dú)立開展研究工作;

2.協(xié)助指導(dǎo)研究生工作以及撰寫論文或基金申請;

3.協(xié)助PI管理實(shí)驗(yàn)室。

2)任職要求

1.以第一作者身份在領(lǐng)域內(nèi)主流期刊上發(fā)表過研究論文;

2.有小鼠腫瘤模型,免疫治療,AAV基因治療等實(shí)驗(yàn)背景者優(yōu)先考慮;

3.具備獨(dú)立開展科研工作和指導(dǎo)研究生能力,有實(shí)驗(yàn)室管理經(jīng)驗(yàn)優(yōu)先考慮;

4.具備流利的英語讀寫和日常交流能力,能夠使用英文撰寫論文。

02博士后

1)主要職責(zé)

1.在PI指導(dǎo)下獨(dú)立開展研究工作;

2.協(xié)助指導(dǎo)研究生工作以及撰寫論文或基金申請。

2)任職要求

1.具有生命科學(xué)或其他相關(guān)生物醫(yī)學(xué)領(lǐng)域的研究背景,即將獲得博士學(xué)位或已獲得博士學(xué)位(原則上不超過3年);

2.以第一作者身份在領(lǐng)域內(nèi)主流期刊上發(fā)表過或即將發(fā)表研究論文,能夠獨(dú)立開展研究工作;

3.具備獨(dú)立開展科研工作和指導(dǎo)研究生能力,具有科研熱情和嚴(yán)謹(jǐn)?shù)目蒲袘B(tài)度;

4.熟練掌握分子生物學(xué)、免疫細(xì)胞培養(yǎng)、動物實(shí)驗(yàn)基本操作和原理;

5.具備良好的英語讀寫和日常交流能力,能夠使用英文撰寫論文。

七、福利待遇

1.根據(jù)應(yīng)聘者的工作經(jīng)驗(yàn)和能力,提供具有市場競爭力的薪酬(詳情面談);

2.享受五險(xiǎn)一金、帶薪年假、體檢和補(bǔ)充醫(yī)療保險(xiǎn)等;

3.支持個人職業(yè)發(fā)展,提供必要的工作相關(guān)專業(yè)培訓(xùn)。

八、申請方法

應(yīng)聘者請將個人簡歷、研究興趣或計(jì)劃,以及2-3名推薦人(僅限博士后應(yīng)聘)的姓名及聯(lián)系方式,以及其他能證明科研能力的相關(guān)電子文件發(fā)送到郵箱zhouxin@cimrbj.ac.cn,郵件主題請注明“應(yīng)聘者名字+具體應(yīng)聘職位”。

聯(lián)系人:老師

聯(lián)系地址:北京市豐臺區(qū)右安門外西頭條10號-首都醫(yī)學(xué)科學(xué)創(chuàng)新中心

本招聘長期有效,至招聘到合適人選為止。

另外本實(shí)驗(yàn)室歡迎有對細(xì)胞免疫療法感興趣的各階段實(shí)習(xí)生、聯(lián)培生前來學(xué)習(xí)交流。

ABOUT CIMR

The Chinese Institutes for Medical Research (CIMR) is a newly founded institution dedicated to fundamental and translational medical research.The CIMR is located at the main campus of the Capital Medical UniversityBeijingChina and committed to building a scientist-centered governance framework and fostering a diverse and inclusive work environment.For more information, please visit our website: www.cimrbj.ac.cn

Laboratory Introduction

Chimeric antigen receptor cell immunotherapy (CAR-T) is a new type of immunotherapy that engineers’ human immune cells to kill tumors.It has achieved remarkable results in leukemia, lymphoma, and multiple myeloma, and there are currently many commercial products worldwide.However, significant challenges remain in enhancing its efficacy against solid tumors.The Zhou Laboratory at CIMR is dedicated to developing and optimizing next-generation CAR-T cell therapies, with a particular focus on innovative cell engineering strategies to improve their effectiveness in solid tumors.

Lab website:

QR code(請點(diǎn)擊鏈接查看詳情)

Major Research Projects

The laboratory will comprehensively utilize molecular biology, cell biology, flow cytometry, mouse tumor models, high-throughput sequencing, and other technologies and methods to research the following topics (not limited):

a.Explore the potential of CAR-NKT cell therapy in pancreatic cancer and other solid tumors.

b.Develop and refine new strategies to enhance CAR-T cell persistence, improving the effectiveness of CAR-T therapy in solid tumors.

c.High-throughput sequencing screening to understand the mechanism of tumor cell tolerance to CAR-T therapy, to guide targeted combined treatment methods.

Major Contributions

a.Generating the murine CAR NKT platform and demonstrating their superior anti-tumor effect in multiple solid tumors via programming the tumor microenvironment (Nature Cancer, 2024).

b.Enhancing the efficacy of CAR-T treatment by modifying CAR structure (Journal for Immunotherapy of Cancer, 2021; Nature Cancer, 2021; Cellular & Molecular Immunology, 2024) (Patent, 2021, WO2023199069A1).

c.Identifying the new mechanism to regulate inflammation and macrophage polarization (Cell Reports, 2019, 2020; The Journal of Clinical Investigation, 2015).

Representative Publications

Nature Cancer, 2024 Nov; 5(11): 1607-1621.PMID: 39354225.

Cellular & Molecular Immunology, 2024 Aug; 21(8): 905-917.PMID: 38937625.

Journal for Immunotherapy of Cancer, 2021 Apr; 9(4): e002173.PMID: 33795386.

Cell Reports.2019 Apr 23; 27(4): 1176-1189.e5.PMID: 31018132.

Open Positions

Research Assistant Investigator

Main Responsibilities

a.Ability to independently conduct scientific research and guide graduate students, experience in laboratory management is preferred

b.Getting involved in lab data analysis and management.

c.Assist in guiding other lab members and writing papers or funding applications.

Qualifications

a.Published or about to publish research papers as the first author in reputable journals in the field.

b.Research experience in mouse tumor models, immunotherapy, AAV gene therapy etc.are preferred.

c.Self-motivated researcher with good communication skills and teamwork ability.

d.Proficient in English reading, writing, and daily communication.

Postdoctoral Researcher

Main Responsibilities

a.Conducting research projects independently.

b.Assisting PI to mentor graduate students, and write grant proposals and manuscripts.

Qualifications

a.Backgrounds in biology or biomedical fields.Either about obtaining a Ph.D.or recently obtaining a Ph.D.degree (ideally within the last 3 years).

b.Published or about to publish research papers as the first author in reputable journals in the field.

c.Have the ability to independently carry out scientific research and guide graduate students and have scientific research enthusiasm and rigorous scientific research attitude.

d.Strong research experience in molecular biology, immune cell culture, FACS, and mice experiments.

e.Proficient in English reading, writing, and daily communication.Capable of writing papers in English.

Welfare Treatment

a.Competitive salary based on the applicant’s work experience and ability (salary negotiable).

b.Social insurance and housing fund, supplementary medical insurance, physical examination and paid annual leave.

c.Opportunities for career development and available professional guidance.

How to apply

To apply, please send a personal resume, research interest or plan, the names and contacts of 2-3 referees, and other materials demonstrating research capabilities to zhouxin@cimrbj.ac.cn and indicate the applicant's name and specific job position in the email subject.

Contact Person: Xin Zhou

This recruitment is valid for the long term until a suitable candidate is recruited.

Additionally, our laboratory welcomes interns and joint trainees at all stages who are interested in cellular immunotherapy to come and exchange ideas.

信息來源于網(wǎng)絡(luò),如有變更請以原發(fā)布者為準(zhǔn)。

來源鏈接:

https://mp.weixin.qq.com/s/WqffOH7gNRlMAS8uMYLdnQ

為防止簡歷投遞丟失請抄送一份至:boshijob@126.com(郵件標(biāo)題格式:應(yīng)聘職位名稱+姓名+學(xué)歷+專業(yè)+中國博士人才網(wǎng))

中國-博士人才網(wǎng)發(fā)布

聲明提示:凡本網(wǎng)注明“來源:XXX”的文/圖等稿件,本網(wǎng)轉(zhuǎn)載出于傳遞更多信息及方便產(chǎn)業(yè)探討之目的,并不意味著本站贊同其觀點(diǎn)或證實(shí)其內(nèi)容的真實(shí)性,文章內(nèi)容僅供參考。

相關(guān)文章
东阿县| 泌阳县| 佛山市| 万宁市| 天柱县| 突泉县| 扬州市| 清河县| 阳城县| 大厂| 鞍山市| 盘锦市| 房产| 务川| 安达市| 察隅县| 定南县| 柏乡县| 鄢陵县| 定边县| 沙田区| SHOW| 新乐市| 农安县| 绥阳县| 新巴尔虎右旗| 巫溪县| 台北市| 泗阳县| 依兰县| 衡山县| 上蔡县| 房山区| 安宁市| 上杭县| 威宁| 慈利县| 庆阳市| 青海省| 石棉县| 门源|